A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT05816252
- Locations
- 🇦🇺
St Vincent's Hospital - Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05642780
- Locations
- 🇺🇸
Community Clinical Research Center, Anderson, Indiana, United States
🇺🇸Westchester Medical Center, Hawthorne, New York, United States
🇺🇸Texas Oncology, P.A. Austin, TX, Austin, Texas, United States
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT04152499
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸BRCR Medical Center, Inc, Plantation, Florida, United States
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03602079
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸Stephenson Cancer Center, Oklahoma City, Oklahoma, United States